Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla., Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presentation at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit that featured tecarfarin historical data and Cadrenal's proposed clinical trial protocol to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 (HM3

PONTE VEDRA, Fla., Nov. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today provided a corporate update coinciding with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Recent Highlights In early September, Cadrenal leadership met with the U.S. Food and Drug Ad

PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 285,715 shares of common stock of the originally issued in July 2023, having an exercise price of $26.25 per share, at a reduced exercise price of $16.50 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective pos

PONTE VEDRA, Fla., Oct. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced that is has raised gross proceeds of approximately $5.1 million through its at-the-market (ATM) facility, selling an aggregate of 391,243 shares of common stock at a weighted average price of $13.15 per share. Fo

Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla., Oct. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to improve anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced its membership in the Corporate Council of the Anticoagulation Forum (AC Forum). The AC Forum is the largest professional organization

PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, announced today it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024. Company Webcast Cadrenal's

PONTE VEDRA, Fla., Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it will be engaging with the U.S. Food and Drug Administration (FDA) in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients.

MIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteM

Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations  Tecarfarin, a novel vitamin K antagonist (VKA), uses a different metabolic pathway than warfarin, the most commonly used anticoagulant for LVAD patients, and may offer more stable and effective anticoagulationPONTE VEDRA, Fla., Aug. 20, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation VKA oral and reversible anticoagulant (blood thinner) designed to

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Info

SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

3 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Mr. Cole brings over 25 years of

PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees. Lisicki brings over 25 years of experience in the pharma/biotech sector, including as the Chief Commercial Officer of Arena Pharmaceuticals, where he provided global visionary leadership for the $6.7 billion growth-stage biopharmaceutical company through their acquisition by Pfizer in Mar

S-3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

D - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

424B5 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 price target.

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in the ARIES-HM3 trial with better patient outcomesPONTE VEDRA, Fla., June 3, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking prese

Gainers Larimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock rose 6.53% to $8.31. The company's market cap stands at $11.4 million. As per the press release, Q1 earnings came out 3 days ago. DermTech (NASDAQ:DMTK) shares moved upwards by 5.52% to $0.38. The market value of their outstanding shares is at $13.2 million. As per the news, the Q1 earnings report came out 4 days ago. BiomX (AMEX:PHGE) shares rose 5.38% to $0.36. The company's market cap stands at $19.8 million. Sharecare (NASDAQ:SHCR) shares rose 4.99% to $0.88. The market value of their ou

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 79.17 percent increase over losses of $(0.48) per share from the same period last year.

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 price target.

Gainers Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.0% to $10.16 during Tuesday's regular session. The market value of their outstanding shares is at $230.0 million. BioSig Technologies (NASDAQ:BSGM) stock increased by 27.41% to $1.58. The market value of their outstanding shares is at $14.7 million. Syros Pharmaceuticals (NASDAQ:SYRS) shares moved upwards by 24.44% to $5.6. The market value of their outstanding shares is at $148.1 million. Inspire Veterinary (NASDAQ:IVP) shares increased by 19.13% to $0.06. The company's market cap stands at $1.7 million. As per the news, the Q4 earnings report came out yesterday. Addex Therapeutics (NASDAQ:ADXN) shares moved upwards b

FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 price target.